Table 3. Clinical and familial features of the patients included in the study.

Sample	Age (years)	Gender	Cancer Type	Tumor Histological Features	Other Tumor Features	Age diagnosis (years)	Familial cancer history	Family members with cancer
								Number	Tumor type	Degree	Youngest age at diagnosis (years)
Patient 1	31	Female	Breast cancer	Canalicular carcinoma	ER (+), PR (+) and Her2/neu (+)	31	Yes	5	Bilateral BC, Unilateral BC Bladder cancer	1st, 2nd and 3rd	22
Patient 2	35	Female	Unilateral Breast cancer	Canalicular carcinoma	ER (+), PR (+) and Her2/neu (−)	30	Yes	5	Breast cancer. Colorectal cancer	1st and 2nd	36
Patient 3	42	Female	Ovarian cancer	Ovarian serous adenocarcinoma	Not reported	33	No
			Unilateral Breast cancer	Canalicular carcinoma	Triple negative	38
Patient 4	40	Female	Unilateral breast cancer	In situ, canalicular carcinoma	ER (+), PR (+) and Her2/neu (−)	38	Yes	3	Breast cancer	1st and 2nd	42
Patient 5	64	Female	Unilateral breast cancer	Canalicular carcinoma	ER (+), PR (+)	63	Yes	2	Breast cancer	1st	51
Patient 6	66	Female	Unilateral breast cancer	Canalicular carcinoma	ER (+), PR (+)	53	Yes	10	Breast cancer. Ovarian cancer. Lymphoma. Intestinal cancer.	1st, 2nd and 3rd.	40
Patient 7	29	Female	Unilateral breast cancer	Canalicular carcinoma	Triple negative	28	Yes	5	Breast, pancreatic, colorectal and bladder cancer	2nd	47
Patient 8	48	Female	Breast cancer	Canalicular carcinoma	NA	47	Yes	2	Breast cancer. Ovarian cancer.	1st	41
Patient 9	42	Female	Breast cancer	Canalicular carcinoma	NA	41	Yes	2	Breast cancer. Ovarian cancer	1st	45
Patient 10	68	Female	Breast cancer	Canalicular carcinoma	ER (+), PR (+)	60	Yes	13	Breast, pancreatic, lung, liver and colorectal cancer	2nd and 3rd	44
Patient 11	53	Female	Unilateral breast cancer	Canalicular carcinoma	ER (+), PR (+) and Her2/neu (−)	49	Yes	13	Breast, pancreatic, lung, liver and colorectal cancer	2nd and 3rd	44
Patient 12	68	Male	Unilateral breast cancer and colorectal cancer	Breast: Canalicular carcinoma.	NA	Colorectal cancer: 52 Breast cancer: 56	Yes	1	Breast cancer	1st	39
Patient 13	62	Female	Bilateral breast cancer	Multifocal, canalicular carcinoma	ER (+), PR (+) and Her2/neu (−)	1st: 48, 2nd: 60	Yes	5	Breast, ovarian and skin cancer	1st and 2nd	36
Patient 14	37	Female	Unilateral breast cancer	Canalicular carcinoma	Triple negative	35	Yes	6	Breast, prostatic and renal cancer	1st and 2nd	28
Patient 15	37	Female	Ovarian cancer	Ovarian serous adenocarcinoma	Not reported	24	Yes	6	Breast, laryngeal, lung, gastric and colorectal.	2nd and 3rd	28
			Unilateral breast cancer (right)	Canalicular carcinoma, brisk lymphocytic infiltrate	ER (+), PR (+) and Her2/neu (−)	37
Patient 16	30	Female	Unilateral breast cancer	Canalicular carcinoma	ER (+), PR (+) and Her2/neu (−)	28	Yes	1	Abdominal cancer (NA)	1st	31
Patient 17	33	Female	Unilateral breast cancer	Canalicular carcinoma	ER (+), PR (+) and Her2/neu (−)	30	Yes	1	Breast and ovarian cancer	1st	55
Patient 18	42	Female	Bilateral breast cancer	Canalicular carcinoma	Triple negative (both tumors)	1st: 34, 2nd: 39	Yes	1	Breast cancer	1st	41
Patient 19	39	Female	Unilateral breast cancer	Canalicular carcinoma	Triple negative	36	Yes	7	Breast cancer	1st, 2nd and 3rd	<40 (NA)
Patient 20	65	Male	Unilateral breast cancer	Lobulillar carcinoma	Triple negative, androgen negative	63	Yes	1	Ovarian cancer	1st	44
Patient 21	28	Female	Unilateral breast cancer	Canalicular carcinoma	Triple negative	27	Yes	2	Laringeal cancer and abdominal caáncer (NA)	2nd	50
Patient 22	35	Female	Unilateral breast cancer	Canalicular carcinoma	Triple negative	32	Yes	2	Prostatic cancer	2nd	58
Patient 23	33	Female	Unilateral breast cancer	Canalicular carcinoma	ER (+), PR (+) and Her2/neu (+)	32	NA (no contact with family)	NA	NA	NA	-
Patient¶24	58	Female	Unilateral breast cancer	Canalicular carcinoma	ER (−), PR (−) and Her2/neu (+)	56	Yes	2	Breast and colorectal cancer	1st	33
Patient 25	48	Female	Unilateral breast cancer	Canalicular carcinoma	NA	37	Yes	2	Breast and gastric cancer	2nd	40
Patient 26	31	Female	Unilateral breast cancer	Canalicular carcinoma	ER (+), PR (+) and Her2/neu (+)	29	Yes	4	Skin, laringeal and intestinal cancer	2nd and 3rd	35
Patient 27	35	Female	Unilateral breast cancer	Canalicular carcinoma	Triple negative	33	Yes	1	Abdominal cancer (NA)	2nd	30
Patient 28	30	Female	Unilateral breast cancer	Canalicular carcinoma	Triple negative	25	Yes	4	Brest, gastric and thyroid cancer	2nd	30
Patient 29	53	Female	Bilateral breast cancer	Canalicular carcinoma	Triple negative	52	Yes	5	Bilateral and unilateral breast cancer. Liver cancer	1st, 2nd and 3rd	40
Patient 30	25	Female	Unilateral breast cancer	Canalicular carcinoma	ER (+), PR (+) and Her2/neu (+)	24	Yes	10	Breast cancer. Prostatic cancer	1st and 2nd	41
Patient 31	41	Female	Unilateral breast cancer	Multifocal, canalicular carcinoma	ER (+), PR (+) and Her2/neu (−)	39	Yes	5	Breast and gastric cancer	1st and 2nd	38
Patient 32	46	Female	Ovarian cancer	Endometrioid carcinoma	Not reported	42	Yes	4	Breast cancer. Ovarian cancer	1st and 2nd	30
Patient 33	61	Female	Unilateral breast cancer	Canalicular carcinoma	ER (+), PR (+) and Her2/neu (−)	56	Yes	3	Breast cancer (Father with breast cancer)	1st and 2nd	31
Patient 34	28	Female	Unilateral breast cancer	Canalicular carcinoma	ER (+), PR (+) and Her2/neu (−)	27	NA (no contact with family)	NA	NA	NA	-
Patient 35	52	Female	Unilateral breast cancer + NF-1	Canalicular carcinoma	ER positive, PR (+)and Her2/neu (−)	46	Yes	2	Breast cancer. Liver cancer	1st	49
Patient 36	60	Female	Unilateral breast cancer + NF-1	Canalicular carcinoma	Triple negative	49	Yes	2	Breast cancer. Liver cancer	1st	46
Patient 37	40	Female	Unilateral breast cancer	Canalicular carcinoma	Triple negative	36	No	-	-	-	-
Patient 38	39	Female	Unilateral breast cancer	Canalicular carcinoma	Triple negative	35	No	-	-	-	-
Patient 39	44	Female	Bilateral breast cancer	Canalicular carcinoma	Triple negative	1st: 27, 2nd: 33	Yes	1	Breast and colorectal cancer	1st	54

ER  =  estrogen receptor; PR  =  progesterone receptor; HER2/neu  =  human epidermal growth factor receptor 2.

NA: Information not available.

NF-1: Neurofibromatosis type 1